uniQure QURE Stock
uniQure Price Chart
uniQure QURE Financial and Trading Overview
| uniQure stock price | 21.78 USD |
| Previous Close | 20.97 USD |
| Open | 21.75 USD |
| Bid | 21.14 USD x 900 |
| Ask | 26.71 USD x 200 |
| Day's Range | 20.76 - 22.55 USD |
| 52 Week Range | 8.73 - 71.5 USD |
| Volume | 1.61M USD |
| Avg. Volume | 2.04M USD |
| Market Cap | 1.56B USD |
| Beta (5Y Monthly) | 1.058 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.03 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 61.24 USD |
QURE Valuation Measures
| Enterprise Value | 1.2B USD |
| Trailing P/E | N/A |
| Forward P/E | -7.612268 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 83.66172 |
| Price/Book (mrq) | 4.8181434 |
| Enterprise Value/Revenue | 64.077 |
| Enterprise Value/EBITDA | -6.541 |
Trading Information
uniQure Stock Price History
| Beta (5Y Monthly) | 1.058 |
| 52-Week Change | -65.044% |
| S&P500 52-Week Change | 16.44% |
| 52 Week High | 71.5 USD |
| 52 Week Low | 8.73 USD |
| 50-Day Moving Average | 40.2 USD |
| 200-Day Moving Average | 29.66 USD |
QURE Share Statistics
| Avg. Volume (3 month) | 2.04M USD |
| Avg. Daily Volume (10-Days) | 2.39M USD |
| Shares Outstanding | 69.37M |
| Float | 57.52M |
| Short Ratio | 2.9 |
| % Held by Insiders | 1.26% |
| % Held by Institutions | 97.84% |
| Shares Short | 8.72M |
| Short % of Float | 12.73% |
| Short % of Shares Outstanding | 12.56% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -872.23% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -15.71% |
| Return on Equity (ttm) | -157.60% |
Income Statement
| Revenue (ttm) | 18.67M USD |
| Revenue Per Share (ttm) | 0.3 USD |
| Quarterly Revenue Growth (yoy) | 11.00% |
| Gross Profit (ttm) | -114707000 USD |
| EBITDA | -182916000 USD |
| Net Income Avi to Common (ttm) | -252208992 USD |
| Diluted EPS (ttm) | -3.97 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 810.33M USD |
| Total Cash Per Share (mrq) | 11.68 USD |
| Total Debt (mrq) | 552.17M USD |
| Total Debt/Equity (mrq) | 170.4 USD |
| Current Ratio (mrq) | 10.01 |
| Book Value Per Share (mrq) | 4.674 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -160787008 USD |
| Levered Free Cash Flow (ttm) | -77580000 USD |
Profile of uniQure
| Country | United States |
| State | N/A |
| City | Amsterdam |
| Address | Paasheuvelweg 25 |
| ZIP | 1105 BP |
| Phone | 31 20 240 6000 |
| Website | https://www.uniqure.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 221 |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Q&A For uniQure Stock
What is a current QURE stock price?
uniQure QURE stock price today per share is 21.78 USD.
How to purchase uniQure stock?
You can buy QURE shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for uniQure?
The stock symbol or ticker of uniQure is QURE.
Which industry does the uniQure company belong to?
The uniQure industry is Biotechnology.
How many shares does uniQure have in circulation?
The max supply of uniQure shares is 69.37M.
What is uniQure Price to Earnings Ratio (PE Ratio)?
uniQure PE Ratio is now.
What was uniQure earnings per share over the trailing 12 months (TTM)?
uniQure EPS is -4.03 USD over the trailing 12 months.
Which sector does the uniQure company belong to?
The uniQure sector is Healthcare.
uniQure QURE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26140.03 USD — |
-2.14
|
8.35B USD — | 26023.1 USD — | 26674.66 USD — | — - | 8.35B USD — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
2932.42 USD — |
-1.69
|
— — | 2925.92 USD — | 2988.49 USD — | — - | — — |
|
US Tech AlphaDEX Multi Cap Growt
NQDXUSMLTCG
US
|
3748.89 USD — |
-2.61
|
— — | 3734.79 USD — | 3849.63 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6824.82 USD — |
-2.56
|
— — | 6805.61 USD — | 7003.77 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1296.28 USD — |
-2.2
|
— — | 1293.25 USD — | 1326.5 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
32291.99 USD — |
-2.14
|
— — | 32147.54 USD — | 32952.44 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12879.53 USD — |
-2.12
|
— — | 12821.14 USD — | 13140.6 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
7457.1 USD — |
-2.56
|
— — | 7436.11 USD — | 7652.63 USD — | — - | — — |
- {{ link.label }} {{link}}
